Funds Advised by Permira Acquire Neuraxpharm from Funds Advised by Apax Partners

September 22, 2020

Funds advised by Permira have agreed to acquire the controlling stake in Neuraxpharm, a leading European specialty pharmaceuticals company focused on central nervous system (CNS) disorders, from funds advised by Apax Partners. Financial terms were not disclosed; Neuraxpharm had annual revenues in excess of €460 million and around 850 employees under Apax's ownership.

Targets
Neuraxpharm
Sellers
Funds advised by Apax Partners
Industry
Pharmaceuticals
Location
Spain
Transaction Type
Buyout

Explore More

Related Acquisitions

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.